New drug combo aims to wipe out lingering cancer cells after standard treatment
NCT ID NCT05343013
Summary
This study is testing whether the drug TAS-102, with or without the anti-inflammatory celecoxib, can clear tiny amounts of leftover cancer DNA from the blood of colorectal cancer patients. It's for people who have finished surgery and chemotherapy but still have detectable cancer DNA, suggesting a high risk of the cancer returning. The main goal is to see if 6 months of this treatment can eliminate this residual cancer signal and potentially prevent recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.